Takeda Pharmaceutical (TAK) Q3 2025 earnings review
Pivot Point Achieved: Return to Growth and Guidance Raise
Takeda has successfully navigated the 'trough' caused by the Vyvanse loss of exclusivity (LOE). After a challenging first half, Q3 revenue returned to growth (+4.2% YoY), driven by the Growth & Launch Products (GLP) portfolio which now constitutes nearly half of total revenue. Management raised full-year guidance for Revenue, Core Operating Profit, and Free Cash Flow, signaling confidence that the worst of the generic erosion is in the rearview mirror. The concurrent announcement of Julie Kim (current U.S. Business Unit President) as the next CEO suggests a continuity of strategy with a sharpened focus on the critical U.S. market.
🐂 Bull Case
The Growth & Launch Products portfolio (including Entyvio, Qdenga, and Takhzyro) grew +14.6% YTD at constant exchange rates. This portfolio successfully offset the Vyvanse drag in Q3, proving the company's diversification strategy is working.
Core Operating Profit margin expanded to 27.9% in Q3 from 25.0% a year prior. Efficiency programs are yielding tangible results, allowing Takeda to raise Core Operating Profit guidance by 20.0 billion JPY despite inflationary pressures.
🐻 Bear Case
Despite the overall turnaround, the Neuroscience segment remains severely impacted, down 31.1% YoY in Q3. While stabilizing, the complete loss of the Vyvanse profit stream continues to weigh on aggregate growth rates compared to peers.
The Rare Diseases segment, traditionally a stronghold, saw a 2.9% revenue decline in Q3. Products like Adzynma and Vonvendi are growing, but older hemophilia franchises (Advate, Feiba) face intense competitive pressure.
⚖️ Verdict: 🟢
Bullish. Takeda executed a 'beat and raise' quarter and confirmed the inflection point in its growth trajectory. The successful absorption of the Vyvanse shock, combined with pipeline progress (Oveporexton, Zasocitinib), positions the company for a strong FY26.
Key Themes
Entyvio Dominance Continues
Accelerating. Entyvio remains the undisputed powerhouse, generating 265.3 billion JPY in Q3 alone, up 17.5% YoY. U.S. growth accelerated to 17.7% in Q3, dispelling fears of market saturation or immediate competitive displacement. The Pen formulation uptake is improving access and patient retention.
Qdenga Vaccine Ramp-Up
Accelerating. The dengue vaccine Qdenga is becoming a material contributor, with Q3 sales hitting 16.7 billion JPY (+65% YoY). YTD sales are 37.7 billion JPY. Demand exceeds supply, and as manufacturing capacity comes online, this will be a durable high-growth asset for the Vaccines segment (which grew 98% in Q3).
Leadership Succession
Christophe Weber will retire in June 2026, to be succeeded by Julie Kim (current U.S. BU President). This is a strategic signal emphasizing the importance of the U.S. market, which accounts for ~50% of revenue. The long transition period (18 months) reduces operational risk but signals no radical strategic deviation.
Neuroscience Reset
Stabilizing at lows. The Vyvanse patent expiry caused a 46% YTD decline in the ADHD franchise. While the worst year-over-year comparables are passing, the segment lacks a near-term commercial replacement of equal magnitude until the orexin franchise (Oveporexton) launches (filed in China, US filing pending).
One-off Accounting Noise
Q3 results included several one-offs: a 29.9 billion JPY COGS adjustment (inventory FX) and a 16 billion JPY R&D reclassification. While Management explained these as technical adjustments, they muddy the water on 'clean' operational cost improvements.
Other KPIs
Accelerating. Up 16.1% YoY. This is a significant reversal from the H1 declines, driven by revenue recovery and OPEX discipline. The margin improved to 27.9%.
Stable/Positive. Up 10.1% YoY (57.6 billion JPY increase). Strong cash conversion enabled the raised full-year FCF guidance and supports the new 100 billion JPY share buyback program.
Accelerating. Up 337% YoY (from 15.01 JPY). While reported numbers are volatile due to non-core items, the directionality confirms improved profitability.
Guidance
Raised by 30 billion JPY. Management cites favorable FX, but implicitly acknowledges better-than-feared Vyvanse erosion and strong GLP performance. Implies Q4 revenue of approx 1,120B JPY.
Raised by 20 billion JPY. Guidance implies a margin of ~25.4% for the full year. This upgrade confirms that efficiency savings are outpacing inflationary headwinds.
Raised from 600-700 billion JPY. Reflects upward revision to Core OP and improvements in working capital. This fully covers the dividend and the new buyback.
Revised upward. Previous guidance was 'Broadly Flat' for revenue but 'Low-single-digit decline' for profit. Now revenue is 'Low-single-digit decline' (which is technically a downgrade from 'Flat' but reflects FX removal). However, the absolute Yen guidance is UP, which matters more for Japanese investors.
Key Questions
Entyvio Peak Sales & IRA Exposure
Entyvio is significantly outperforming near-term. With the potential for IRA negotiation inclusion in 2028, does the current acceleration change your peak sales assumptions or the lifecycle management strategy for the asset?
Rare Disease Divergence
The Rare Disease segment declined nearly 3% this quarter while other core segments grew. Is this a structural decline due to competitive intensity in Hemophilia (Advate/Adynovate), and should we expect this segment to be a drag on growth in FY26?
Oveporexton Launch Curve
With the NDA submission for Oveporexton planned, how should we model the launch curve given the diagnostic bottlenecks in narcolepsy? Will the launch require significantly higher SG&A investment in FY26 compared to FY25?